Domov › Nemalobunkový karcinóm pľúc › New York › Syracuse
Klinické štúdie Nemalobunkový karcinóm pľúc v meste Syracuse, NY
15 štúdií pre Nemalobunkový karcinóm pľúc hľadá účastníkov v zariadeniach v meste Syracuse a okolí (do cca 30 míľ). Otvorte štúdiu a zistite, kto sa môže zapojiť a ako kontaktovať tím.
Oficiálny text štúdie (anglicky)
Hľadáte účastníkov do štúdie? Zvýraznite ju na začiatku tejto stránky – $99 na 30 dní →
Testing the Impact of an Anti-Cancer Drug, Atezolizumab, After Surgery to Prevent Early Stage Non-small Cell Lung Cancer From Returning, AASI-NSCLC Trial
Prebieha náborFáza 3
- Hematology Oncology Associates of Central New York-East Syracuse, East Syracuse · 4 míľ odtiaľ
- Hematology Oncology Associates of CNY at Camillus, Camillus · 8 míľ odtiaľ
Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])
Prebieha náborFáza 3
- State University of New York Upstate Medical University, Syracuse
- SUNY Upstate Medical Center-Community Campus, Syracuse
- Hematology Oncology Associates of Central New York-East Syracuse, East Syracuse · 4 míľ odtiaľ
- a 1 ďalších
A Study of Targeted Post-Surgery Radiation Therapy for Non-Small Cell Lung Cancer With Remaining Lymph Node Cancer After Treatment
Prebieha náborFáza 2
- State University of New York Upstate Medical University, Syracuse
- Upstate Cancer Center at Hill Radiation Oncology, Syracuse
A Study of Pembrolizumab (MK-3475) With or Without Intismeran Autogene (V940) in Participants With Non-small Cell Lung Cancer (V940-009/INTerpath-009)
Prebieha náborFáza 3
- SUNY Upstate Cancer Center ( Site 0140), Syracuse
- Hematology-Oncology Associates of CNY ( Site 0164), East Syracuse · 4 míľ odtiaľ
Study of Zanzalintinib in Combination With Immuno-Oncology or Other Agents in Participants With Solid Tumors
Prebieha náborFáza 1
- Exelixis Clinical Site #76, Syracuse
A Global Phase III Study of Rilvegostomig or Pembrolizumab Monotherapy for First-Line Treatment of PD-L1-high Metastatic Non-small Cell Lung Cancer
Prebieha náborFáza 3
- Research Site, East Syracuse · 4 míľ odtiaľ
A Study of Amivantamab in Combination With Lazertinib, or Amivantamab in Combination With Platinum-Based Chemotherapy, for Common Epidermal Growth Factor Receptor (EGFR)-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)
Prebieha náborFáza 2
- Hematology-Oncology Associates of CNY, East Syracuse · 4 míľ odtiaľ
A Study to Compare the Efficacy of Nivolumab and Relatlimab Plus Chemotherapy vs Pembrolizumab Plus Chemotherapy for Stage IV/Recurrent Non-squamous Non-small Cell Lung Cancer With PD-L1 Expression ≥ 1%
Prebieha náborFáza 3
- SUNY Upstate Medical University, Syracuse
A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Locally Advanced or Metastatic Squamous Non-small Cell Lung Cancer (NSCLC)
Prebieha náborFáza 3
- Research Site, East Syracuse · 4 míľ odtiaľ
Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patients With High PD-L1
Prebieha náborFáza 3
- Clinical Study Site, Syracuse
A Study Evaluating the Efficacy and Safety of Divarasib and Pembrolizumab Versus Pembrolizumab and Pemetrexed and Carboplatin or Cisplatin in Participants With Previously Untreated, KRAS G12C-Mutated, Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer
Prebieha náborFáza 3
- SUNY Upstate Medical University, Syracuse
Phase III Study of Datopotamab Deruxtecan Versus Docetaxel in Previously Treated TROP2-positive Advanced or Metastatic Non-squamous NSCLC Without Actionable Genomic Alterations
Prebieha náborFáza 3
- Research Site, East Syracuse · 4 míľ odtiaľ
Radiotherapy to Block Oligoprogression In Metastatic Non-Small-Cell Lung Cancer
Prebieha náborFáza 3
- State University of New York Upstate Medical University, Syracuse
JoLT-Ca Sublobar Resection (SR) Versus Stereotactic Ablative Radiotherapy (SAbR) for Lung Cancer
Prebieha náborFáza 3
- SUNY - Upsate Medical Centre, Syracuse
GEMINI-NSCLC: NSCLC Biomarker Study
Prebieha náborObservačná štúdia
- Hematology Oncology Associates of Central New York, East Syracuse · 4 míľ odtiaľ
Štúdie Nemalobunkový karcinóm pľúc v iných mestách
- Houston, TX145 štúdií
- New York City, NY121 štúdií
- Arlington, VA104 štúdií
- Nashville, TN97 štúdií
- Boston, MA90 štúdií
- Los Angeles, CA87 štúdií
- St. Louis, MO73 štúdií
- Chicago, IL61 štúdií
- Baltimore, MD60 štúdií
- San Antonio, TX59 štúdií
- Columbus, OH57 štúdií
- Washington, DC55 štúdií
Iné štúdie v Syracuse
- Rakovina (všetky typy)9 štúdií
- Rakovina prostaty9 štúdií
- Nemuskulárne invazívny karcinóm močového mechúra8 štúdií
- Rakovina vaječníkov7 štúdií
- Rakovina endometria7 štúdií
- Obézita6 štúdií
- Rakovina pľúc6 štúdií
- Kolorektálny karcinóm5 štúdií
- Makulárna degenerácia5 štúdií
- Akútna myeloidná leukémia5 štúdií
- Diabetes mellitus 2. typu5 štúdií
- Lupus5 štúdií
Z ClinicalTrials.gov, dáta načítané 6. 10. 2026. Každá štúdia má vlastné kritériá oprávnenosti; tím štúdie rozhoduje o účasti.